• Edesa Biotech flagged Phase 3 results for paridiprubart (EB05), its anti-TLR4 antibody for acute respiratory distress syndrome, as focus of upcoming presentations at American Thoracic Society meetings in May 2026.
• Two sets of Phase 3 results have already been reported, covering an initial group of 104 patients on invasive mechanical ventilation, then an expanded 278-patient population including ventilated and non-ventilated patients.
• Management framed expanded findings as reinforcing potential clinical benefit, positioning drug as possible new option in a condition with limited effective treatments.
• CEO Par Nijhawan is slated to present study findings May 15, 2026 at ATS Respiratory Innovation Summit oral showcase.
• Principal investigator Ted Steiner is scheduled to present Phase 3 results May 20, 2026 at about 8:30 a.m. ET during ATS 2026 International Conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.